Inactive Instrument

Pacgen Life Science Corporation Share Price

Equities

PBS

CA69374M1041

Biotechnology & Medical Research

Dynamic Chart
General Biologicals Corporation completed the acquisition of additional 77% stake in Pacgen Life Science Corporation. CI
Pacgen Life Science Corporation Reports Earnings Results for the First Quarter Ended June 30, 2020 CI
Pacgen Life Science Corporation Reports Earnings Results for the Full Year Ended March 31, 2020 CI
General Biologicals Corporation entered into a letter of intent to acquire additional 77% stake in Pacgen Life Science Corporation for CAD 1.4 million. CI
Pacgen Life Science Corporation Reports Earnings Results for the Third Quarter Ended December 31, 2019 CI
Pacgen Life Science Corporation Reports Earnings Results for the Second Quarter Ended September 30, 2019 CI
Pacgen Life Science Corporation Reports Earnings Results for the First Quarter Ended June 30, 2019 CI
Pacgen Life Science Corporation Reports Earnings Results for the Full Year Ended March 31, 2019 CI
Pacgen Life Science Corporation Reports Earnings Results for the Third Quarter Ended December 31, 2018 CI
Pacgen Life Science Corporation Announces Management Changes CI
Pacgen Life Science Corporation Appoints Rakesh Arya as Board of Directors CI
Pacgen Life Science Corporation announced that it has received CAD 0.74 million in funding CI
Pacgen Life Science Corporation Gains Exclusive Global Commercial Rights to DermaMed, DermaSoleil and Deserving Health CI
Pacgen Life Science Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2015 CI
Pacgen Life Science Corporation announced that it has received CAD 0.32 million in funding from Southern Gold Resources Ltd and other investors. CI
More news
Managers TitleAgeSince
Chief Executive Officer - 10/06/10
Founder - -
Chief Executive Officer 80 23/04/23
Members of the board TitleAgeSince
Director/Board Member 70 01/10/01
Chief Executive Officer 80 23/04/23
Chief Executive Officer - 10/06/10
More insiders
Pacgen Life Science Corporation, formerly Pacgen Biopharmaceuticals Corporation, is a life sciences company focused on the commercialization of life sciences products and services. The Company has a worldwide license to develop and commercialize an antifungal called P113 (also called PAC-113). It has sublicensed its PAC-113 right to General Biologicals Corporation (GBC), which offers non-prescription over-the-counter (OTC) products containing PAC-113 in Taiwan. P113 is a 12 amino-acid antimicrobial peptide derived from a histatin protein found in saliva. Its P113 is used for the treatment of various oral conditions, as well as vaginal, dermatological and ophthalmic conditions. GBC offers products, such as cosmetic skin-care products, oral hygiene products and intimate hygiene products. The oral healthcare product includes Mr.&Mrs.O. It has conducted a Phase IIb dose-ranging clinical trial for PAC-113. Its oral health and woman health products are in the commercialization stage.
More about the company